ANVS
Annovis Bio, Inc. [ANVS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ANVS Stock Summary
Top 10 Correlated ETFs
ANVS
Top 10 Correlated Stocks
ANVS
In the News
ANVS Financial details
Company Rating
Neutral
Market Cap
128.06M
Income
-75.91M
Revenue
0
Book val./share
-0.81
Cash/share
0.6
Dividend
-
Dividend %
-
Employees
6
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-2.07
Forward P/E
-
PEG
-0.12
P/S
-
P/B
17.62
P/C
16.42
P/FCF
-4.27
Quick Ratio
1.78
Current Ratio
2.87
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-8.62
EPS next Y
-
EPS next Q
-
EPS this Y
102.27%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
42.94%
-
-
-
-
SMA20
13.71%
SMA50
4.78%
SMA100
78.05%
Inst Own
8.48%
Inst Trans
0.54%
ROA
-555%
ROE
-299%
ROC
-2.65%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
5.42-22.49
52W High
-55.23%
52W Low
+97%
RSI
43.29
Rel Volume
0.99
Avg Volume
244.62K
Volume
241.57K
Perf Week
-14.27%
Perf Month
5.35%
Perf Quarter
21.16%
Perf Half Y
18.11%
-
-
-
-
Beta
1.589
-
-
Volatility
1.09%, 1.21%
Prev Close
9.57%
Price
9.85
Change
-1.5%
ANVS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.04 | -0.67 | -1.89 | -3.08 | -6.23 | |
| Operating cash flow per share | -0.07 | -0.63 | -1.2 | -2.12 | -4.43 | |
| Free cash flow per share | -0.07 | -0.63 | -1.2 | -2.12 | -4.43 | |
| Cash per share | 0 | 1.28 | 5.99 | 3.48 | 0.64 | |
| Book value per share | -1.25 | 1.2 | 5.83 | 3.47 | -0.86 | |
| Tangible book value per share | -1.25 | 1.2 | 5.83 | 3.47 | -0.86 | |
| Share holders equity per share | -1.25 | 1.2 | 5.83 | 3.47 | -0.86 | |
| Interest debt per share | -5.91 | 7.49 | 0 | -0.02 | 0 | |
| Market cap | 65.65M | 47.57M | 134.07M | 109.62M | 168.73M | |
| Enterprise value | 66.15M | 39.49M | 88.38M | 81.24M | 162.98M | |
| P/E ratio | -221.16 | -11.17 | -9.29 | -4.36 | -3 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -137.76 | -11.98 | -14.68 | -6.33 | -4.22 | |
| PFCF ratio | -137.76 | -11.98 | -14.68 | -6.33 | -4.22 | |
| P/B Ratio | -7.65 | 6.31 | 3.01 | 3.87 | -21.77 | |
| PTB ratio | -7.65 | 6.31 | 3.01 | 3.87 | -21.77 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -83.62 | -7.24 | -6.1 | -3.18 | -3.62 | |
| EV to operating cash flow | -138.8 | -9.95 | -9.68 | -4.69 | -4.08 | |
| EV to free cash flow | -138.8 | -9.95 | -9.68 | -4.69 | -4.08 | |
| Earnings yield | 0 | -0.09 | -0.11 | -0.23 | -0.33 | |
| Free cash flow yield | -0.01 | -0.08 | -0.07 | -0.16 | -0.24 | |
| Debt to equity | -0.06 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0.45 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | -0.63 | 1.48 | 3.15 | 1.11 | 0.13 | |
| Current ratio | 0.37 | 14.04 | 30.54 | 4.68 | 2.39 | |
| Interest coverage | 0.04 | -0.14 | 0 | 139.63 | 0 | |
| Income quality | 0.48 | 0.73 | 0.63 | 0.68 | 0.71 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.11 | 4.26 | 15.76 | 15.51 | 10.97 | |
| ROIC | 0.06 | -0.69 | -0.33 | -0.89 | 5.81 | |
| Return on tangible assets | -0.27 | -0.52 | -0.31 | -0.7 | -5.51 | |
| Graham Net | -55.8 | 1.19 | 5.79 | 2.53 | -1.35 | |
| Working capital | -1.26M | 7.54M | 44.49M | 28.32M | 5.93M | |
| Tangible asset value | -8.58M | 7.54M | 44.49M | 28.32M | -7.75M | |
| Net current asset value | -8.95M | 7.54M | 44.49M | 28.32M | -7.75M | |
| Invested capital | -0.06 | 0 | 0 | 0 | 0 | |
| Average receivables | 367.54K | 367.54K | 0 | 0 | 0 | |
| Average payables | 651.15K | 787.87K | 514.97K | 2.32M | 2.63M | |
| Average inventory | -372.82M | -372.82M | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.03 | -0.56 | -0.32 | -0.89 | 7.25 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.37 | -3.59 | -1.07 | -1.63 | -2.33 | |
| Operating cash flow per share | -0.44 | -1.42 | -1.07 | -0.71 | -0.98 | |
| Free cash flow per share | -0.44 | -1.42 | -1.07 | -0.71 | -0.98 | |
| Cash per share | 3.48 | 2.05 | 1.76 | 0.71 | 0.6 | |
| Book value per share | 3.47 | 2.46 | 2.32 | 0.74 | -0.81 | |
| Tangible book value per share | 3.47 | 2.46 | 2.32 | 0.74 | -0.81 | |
| Share holders equity per share | 3.47 | 2.46 | 2.32 | 0.74 | -0.81 | |
| Interest debt per share | -0.01 | 2.4 | 0 | 0 | 0 | |
| Market cap | 109.64M | 126.28M | 127.91M | 85.53M | 178.13M | |
| Enterprise value | 81.26M | 109.53M | 112.19M | 79.17M | 172.37M | |
| P/E ratio | -9.07 | -1.07 | -3.35 | -1.45 | -2 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -30.38 | -10.86 | -13.32 | -13.3 | -19.02 | |
| PFCF ratio | -30.38 | -10.86 | -13.32 | -13.3 | -19.02 | |
| P/B Ratio | 3.87 | 6.27 | 6.17 | 12.85 | -22.98 | |
| PTB ratio | 3.87 | 6.27 | 6.17 | 12.85 | -22.98 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -25.64 | -10.99 | -11.5 | -5.38 | -16.51 | |
| EV to operating cash flow | -22.51 | -9.42 | -11.68 | -12.31 | -18.41 | |
| EV to free cash flow | -22.51 | -9.42 | -11.68 | -12.31 | -18.41 | |
| Earnings yield | -0.03 | -0.23 | -0.07 | -0.17 | -0.12 | |
| Free cash flow yield | -0.03 | -0.09 | -0.08 | -0.08 | -0.05 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | 8.95 | 1.68 | 1.61 | 0.43 | 0.55 | |
| Current ratio | 4.68 | 4.72 | 11 | 2.87 | 2.39 | |
| Interest coverage | 42.74 | 0.51 | 0 | 0 | 0 | |
| Income quality | 1.17 | 1.19 | 1.01 | 1 | 0.42 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 5.37 | 14.09 | 7.45 | 5.21 | 6.53 | |
| ROIC | -0.11 | 1.5 | -0.47 | -2.23 | 1.35 | |
| Return on tangible assets | -0.08 | -1.15 | -0.42 | -1.44 | -2.18 | |
| Graham Net | 2.53 | 1.38 | 1.53 | 0.31 | -1.28 | |
| Working capital | 28.32M | 20.14M | 20.74M | 6.66M | 5.93M | |
| Tangible asset value | 28.32M | 20.14M | 20.74M | 6.66M | -7.75M | |
| Net current asset value | 28.32M | 20.14M | 20.74M | 6.66M | -7.75M | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 2.9M | 4.06M | 2.66M | 1.55M | 1.61M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.11 | -1.46 | -0.46 | -2.21 | 2.87 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
ANVS Frequently Asked Questions
What is Annovis Bio, Inc. stock symbol ?
Annovis Bio, Inc. is a US stock , located in Berwyn of Pa and trading under the symbol ANVS
What is Annovis Bio, Inc. stock quote today ?
Annovis Bio, Inc. stock price is $9.85 today.
Is Annovis Bio, Inc. stock public?
Yes, Annovis Bio, Inc. is a publicly traded company.
Company Profile
- Volume Average 244.62K
- Market Capitalization 128.06M
- Employee 6
- CEO Dr. Maria L. Maccecchini Ph.D.
- Headquarters Berwyn,PA,US
- IPO Date 2020-01-29
-
Website
https://www.annovisbio.com 
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
